WallStSmart

Decoy Therapeutics Inc. (DCOY)vsRegeneron Pharmaceuticals Inc (REGN)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Regeneron Pharmaceuticals Inc generates 7422560% more annual revenue ($16.90B vs $227,630). REGN leads profitability with a 28.5% profit margin vs 0.0%. DCOY trades at a lower P/E of 0.1x. REGN earns a higher WallStSmart Score of 80/100 (B+).

DCOY

Avoid

25

out of 100

Grade: F

Growth: 4.3Profit: 2.5Value: 6.7Quality: 4.3
Piotroski: 3/9Altman Z: -14.38

REGN

Strong Buy

80

out of 100

Grade: B+

Growth: 8.7Profit: 8.0Value: 7.3Quality: 8.5
Piotroski: 2/9Altman Z: 4.44
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for DCOY.

REGNUndervalued (+36.3%)

Margin of Safety

+36.3%

Fair Value

$1500.88

Current Price

$952.40

$548.48 discount

UndervaluedFair: $1500.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DCOY2 strengths · Avg: 10.0/10
P/E RatioValuation
0.1x10/10

Attractively priced relative to earnings

Price/BookValuation
0.1x10/10

Reasonable price relative to book value

REGN6 strengths · Avg: 9.7/10
Operating MarginProfitability
30.4%10/10

Strong operational efficiency at 30.4%

Revenue GrowthGrowth
36.3%10/10

Revenue surging 36.3% year-over-year

Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.4410/10

Safe zone — low bankruptcy risk

Market CapQuality
$98.40B9/10

Large-cap with strong market position

Profit MarginProfitability
28.5%9/10

Keeps 29 of every $100 in revenue as profit

Areas to Watch

DCOY4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$2.33M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

REGN1 concerns · Avg: 3.0/10
Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : DCOY

The strongest argument for DCOY centers on P/E Ratio, Price/Book.

Bull Case : REGN

The strongest argument for REGN centers on Operating Margin, Revenue Growth, Debt/Equity. Profitability is solid with margins at 28.5% and operating margin at 30.4%. Revenue growth of 36.3% demonstrates continued momentum.

Bear Case : DCOY

The primary concerns for DCOY are Revenue Growth, EPS Growth, Market Cap.

Bear Case : REGN

The primary concerns for REGN are Piotroski F-Score.

Key Dynamics to Monitor

DCOY profiles as a value stock while REGN is a growth play — different risk/reward profiles.

DCOY carries more volatility with a beta of 0.74 — expect wider price swings.

REGN is growing revenue faster at 36.3% — sustainability is the question.

REGN generates stronger free cash flow (1.5B), providing more financial flexibility.

Bottom Line

REGN scores higher overall (80/100 vs 25/100), backed by strong 28.5% margins and 36.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Decoy Therapeutics Inc.

HEALTHCARE · BIOTECHNOLOGY · USA

Decoy Therapeutics Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. The company is headquartered in Cambridge, Massachusetts.

Regeneron Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.

Want to dig deeper into these stocks?